By Counterforce Health Team in Elevidys (delandistrogene moxeparvovec-rokl) —

How to Get Elevidys (delandistrogene moxeparvovec-rokl) Covered by Aetna CVS Health in Pennsylvania: Appeals, Alternatives & Prior Authorization Guide

Quick Answer: Getting Elevidys Covered by Aetna CVS Health in Pennsylvania

Eligibility: Aetna CVS Health covers Elevidys (delandistrogene moxeparvovec-rokl) for DMD patients meeting FDA criteria, but requires prior authorization and treatment at designated GCIT network centers. Fastest path: Submit precertification with genetic confirmation, prior therapy documentation, and specialist attestation. First step today: Call Aetna at 1-800-624-0756 to verify GCIT provider requirements and initiate prior authorization. If denied, Pennsylvania's new external review program overturns ~50% of appeals within 45 days.

Table of Contents

When Alternatives Make Sense

Before pursuing Elevidys appeals, consider whether formulary alternatives might be appropriate for your situation. Aetna CVS Health covers several DMD therapies that may be more accessible while you work toward gene therapy approval.

Alternatives make sense when:

  • Your child doesn't yet meet Elevidys eligibility criteria (age, ambulatory status, genetic profile)
  • You're facing urgent coverage needs and can't wait for GCIT network approval
  • Previous therapies haven't been adequately documented for prior authorization
  • You want to establish treatment history while pursuing gene therapy

Alternatives may not be suitable if:

  • Your child has specific contraindications to corticosteroids or exon-skipping therapies
  • Previous treatments have failed with documented adverse effects
  • Genetic testing shows mutations not addressable by available alternatives

Typical Formulary Alternatives

Aetna CVS Health's formulary includes several FDA-approved DMD therapies, each with specific prior authorization requirements:

Corticosteroids

  • Deflazacort (Emflaza): Often preferred over prednisone for better side effect profile
  • Prednisone/Prednisolone: Standard of care, typically requires prior authorization for DMD indication

Exon-Skipping Therapies

  • Eteplirsen (Exondys 51): For patients amenable to exon 51 skipping (~13% of DMD patients)
  • Golodirsen (Vyondys 53): Targets exon 53 mutations (~8% of patients)
  • Viltolarsen (Viltepso): Alternative exon 53 therapy
  • Casimersen (Amondys 45): For exon 45 mutations (~8% of patients)
Note: All exon-skipping therapies require genetic testing to confirm appropriate mutation and precertification through Aetna's specialty pharmacy process.

Coverage Requirements at a Glance

Requirement Elevidys Exon-Skipping Drugs Corticosteroids
Prior Authorization Always required Always required Usually required
Genetic Testing DMD confirmation Specific exon mutation DMD diagnosis
Site of Care GCIT network only Specialty infusion Any provider
Specialist Required Yes Yes Recommended
Age Restrictions Per FDA label None specified None
Monitoring Hepatic function Kidney function Growth, bone health

Source: Aetna Precertification List 2025

Step-by-Step: Fastest Path to Approval

1. Verify GCIT Network Status

Who: Patient/family
Action: Call Aetna at 1-800-624-0756 to confirm nearest GCIT network provider
Timeline: Same day
Documents needed: Member ID, zip code

2. Gather Required Documentation

Who: Clinical team
Documents needed:

  • Genetic testing confirming DMD diagnosis
  • Ambulatory function assessments
  • Prior therapy history (corticosteroids, other treatments)
  • Current weight and dosing calculations
  • Hepatic function baseline labs
  • Anti-AAV antibody titers

3. Submit Prior Authorization

Who: Prescribing physician
Method: Aetna provider portal or fax to precertification department
Timeline: Submit 2-3 weeks before planned treatment
Required elements: Medical necessity letter, clinical documentation, GCIT provider confirmation

4. Coordinate with CVS Specialty

Who: Clinical coordinator
Action: Contact CVS Specialty at number on member card for logistics coordination
Timeline: After PA approval
Requirements: Site preparation, infusion scheduling, monitoring protocols

Exception Strategy for Elevidys

When standard prior authorization is denied, Aetna CVS Health offers formulary exception processes for non-covered or restricted therapies.

Strongest exception requests include:

  • Detailed clinical rationale for why alternatives are inadequate
  • Published literature supporting gene therapy for patient's specific mutation
  • Documentation of failed prior therapies with specific adverse events
  • Specialist attestation of medical necessity
  • Evidence of functional decline despite standard care

Timeline for exceptions:

  • Standard review: 72 hours after receiving prescriber documentation
  • Expedited review: 24 hours if delay would jeopardize health
From our advocates: We've seen strongest success with exception requests that include specific functional outcome measures (6-minute walk test, timed function tests) showing decline despite optimal standard care, combined with peer-reviewed literature supporting gene therapy for the patient's genetic profile.

Appeals Playbook for Pennsylvania

Pennsylvania's new Independent External Review Program launched in January 2024 has overturned 50% of health insurance denials, making it a powerful tool for specialty drug appeals.

Internal Appeals (Required First Step)

  1. First Level: Submit to Aetna within 180 days of denial
  2. Second Level: Request reconsideration if first appeal denied
  3. Expedited: Available for urgent medical situations (72-hour decision)

Pennsylvania External Review

Eligibility: After exhausting Aetna's internal appeals process
Timeline: 4 months to request after final denial
Process: Submit through Pennsylvania Insurance Department website or call (877) 881-6388
Decision timeline: 45 days for standard review, 72 hours for urgent cases
Success rate: Approximately 50% of denials overturned in 2024

Required documents for external review:

  • Final Adverse Benefit Determination letter from Aetna
  • All medical records supporting medical necessity
  • Prescriber statement of clinical rationale
  • Any additional evidence (within 15 days of assignment)

Switching Logistics

Provider Coordination

When transitioning between DMD therapies or adding Elevidys to existing treatment:

  1. Multidisciplinary planning: Coordinate with neurology, cardiology, pulmonology, and pharmacy teams
  2. Documentation: Record current functional status, treatment response, and adverse events
  3. Monitoring protocols: Establish hepatic function monitoring for Elevidys, adjust other therapy schedules
  4. Communication: Notify CVS Specialty of treatment changes and coordination needs

Specialty Pharmacy Management

CVS Specialty handles most Aetna gene therapy logistics:

  • Prior authorization coordination
  • Site-of-care scheduling
  • Drug shipment and handling
  • Post-infusion monitoring support
  • Insurance benefit coordination

Re-trying for Elevidys Later

If initial attempts for Elevidys coverage fail, document the following during alternative therapy trials to strengthen future requests:

Clinical progression markers:

  • Serial functional assessments (6-minute walk, timed function tests)
  • Pulmonary function trends
  • Cardiac function monitoring
  • Quality of life measures

Treatment response documentation:

  • Efficacy of current therapies
  • Adverse events requiring discontinuation or dose modification
  • Compliance challenges with current regimens

New evidence:

  • Updated genetic testing results
  • Additional clinical trial data
  • Changes in FDA labeling or clinical guidelines

Counterforce Health's platform can help organize this documentation and identify the strongest clinical arguments for future Elevidys authorization requests by analyzing your specific denial reasons against Aetna's coverage criteria.

Common Denial Reasons & Fixes

Denial Reason How to Overturn Required Documentation
Not medically necessary Submit functional decline data 6MWT, TFT, PFT trends over 6-12 months
Experimental/investigational Cite FDA approval and guidelines FDA label, DMD care guidelines, specialist letter
Non-formulary status Request formulary exception Medical necessity letter, prior therapy failures
GCIT network requirement not met Confirm provider designation GCIT provider confirmation, travel hardship documentation if applicable
Inadequate genetic confirmation Submit comprehensive testing Full DMD genetic panel, deletion/duplication analysis
Missing safety monitoring plan Develop comprehensive protocol Hepatic monitoring plan, anti-AAV antibody management

FAQ

How long does Aetna CVS Health prior authorization take in Pennsylvania? Standard PA decisions are made within 14 days of receiving complete documentation. Expedited requests for urgent situations are decided within 72 hours.

What if Elevidys is non-formulary on my plan? Request a formulary exception through Aetna's standard process. Provide detailed medical necessity documentation and evidence that covered alternatives are inadequate.

Can I request an expedited appeal if my child's condition is declining? Yes, both Aetna internal appeals and Pennsylvania external reviews offer expedited processes for urgent medical situations, typically decided within 72 hours.

Does step therapy apply to gene therapy like Elevidys? Aetna typically requires documentation of prior DMD therapies (usually corticosteroids) before approving gene therapy, though this may vary by plan.

What happens if Pennsylvania external review overturns my denial? Aetna must immediately provide coverage, including retroactive coverage if you paid out-of-pocket during the appeal process.

How much does Elevidys cost if I have to pay out-of-pocket? The list price is approximately $3.2 million for the one-time treatment. Sarepta Therapeutics offers patient assistance programs - check their website for current eligibility criteria.

Can I appeal to Pennsylvania if I have a self-funded employer plan? No, self-funded plans are governed by federal ERISA law and are exempt from state external review programs. Contact the plan administrator for appeal options.

What documentation should I keep during the appeals process? Save all denial letters, medical records, correspondence with Aetna, and any out-of-pocket payment receipts. These will be needed for external review if internal appeals fail.

For families navigating complex insurance coverage for rare disease treatments like Elevidys, Counterforce Health provides specialized support in turning insurance denials into successful appeals. Their platform analyzes denial letters against specific payer policies and helps generate evidence-backed appeals that address each plan's unique requirements, potentially saving months in the approval process.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions vary by individual plan and clinical circumstances. Always consult with your healthcare provider and insurance company for guidance specific to your situation. For additional help with insurance appeals in Pennsylvania, contact the Pennsylvania Insurance Department at (877) 881-6388.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.